| Website | domainvc.com |
| Phone | 609-683-5656 |
| Employees | |
| Founded | 1985 |
| Eighth Fund, 4/09 |
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.
Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
| Company | Date | Round | Size | Participants |
| Esperion Therapeutics | 4/13 | Venture Round | $33M | 7 |
| Glaukos | 2/13 | Series F | $30M | 7 |
| Marinus Pharmaceuticals | 1/13 | Series C | $21M | 4 |
| Kona Medical | 12/12 | Series C | $10M | 5 |
| Epic Sciences | 11/12 | Series B | $13M | 3 |
| RightCare Solutions | 10/12 | Series A | $1.75M | 2 |
| ROX Medical | 9/12 | Venture Round | $6M | 2 |
| CoDa Therapeutics | 7/12 | Series B | $20M | 3 |
| BioNano Genomics | 7/12 | Series B | $10M | 3 |
| Benvenue Medical | 6/12 | Series D | $25M | 4 |
| Astute Medical | 6/12 | Series C | $40.4M | 6 |
| Kona Medical | 5/12 | Series C | $30M | 4 |
| Zyga Technology | 5/12 | Series C | $25M | 4 |
| Sequent Medical | 3/12 | Series C | $26M | 4 |
| Apnex Medical | 2/12 | Series C | $20M | 3 |
| Carticept Medical | 1/12 | Series C | $10M | 3 |
| Aria Diagnostics | 1/12 | Series C | $52.7M | 3 |
| IntegenX | 12/11 | Series C | $40M | 7 |
| Sera Prognostics | 11/11 | Series A | $19.3M | 3 |
| CoLucid Pharmaceuticals | 8/11 | Venture Round | $7.5M | 5 |
| CoDa Therapeutics | 4/11 | Series B | $19.2M | 3 |
| Benvenue Medical | 4/11 | Series C | $35.5M | 3 |
| BioNano Genomics | 3/11 | Series B | $23.3M | 4 |
| Astute Medical | 3/11 | Series B | $13M | 4 |
| IntegenX | 2/11 | Series B | $15.6M | 3 |
| aTyr Pharma | 10/10 | Series C | $23M | 4 |
| ProteinSimple | 10/10 | Series F | $20M | 8 |
| Tobira Therapeutics | 9/10 | Series B | $31M | 5 |
| Eddingpharm (Cayman) | 9/10 | Series B | $24M | 3 |
| Celator Pharmaceuticals | 9/10 | Series D | $20M | 7 |
| Otonomy | 8/10 | Series B | $38.5M | 4 |
| Achillion Pharmaceuticals | 8/10 | Venture Round | $50.1M | 4 |
| Nuon Therapeutics | 8/10 | Venture Round | $10M | 3 |
| ReVision Optics | 7/10 | Series D | $35M | 4 |
| Zogenix | 7/10 | Venture Round | $15M | 5 |
| Corridor Pharmaceuticals | 6/10 | Series A | $15M | 8 |
| Veracyte | 6/10 | Series B | $28M | 4 |
| Sequent Medical | 5/10 | Series B | $15.6M | 3 |
| Astute Medical | 5/10 | Series B | $26.5M | 4 |
| Tragara | 4/10 | Series B | $5M | 5 |
| Achaogen | 4/10 | Series C | $56M | 7 |
| Nuon Therapeutics | 3/10 | Venture Round | $6.05M | 3 |
| Syndax Pharmaceuticals | 3/10 | Series A | $9M | 5 |
| Carticept Medical | 3/10 | Series B | $20M | 3 |
| Altair Therapeutics | 2/10 | Series B | $17M | 4 |
| VentiRx Pharmaceuticals | 1/10 | Series A | $51.6M | 4 |
| Regado Biosciences | 12/09 | Series D | $40M | 5 |
| Afferent Pharmaceuticals | 12/09 | Series A | $23M | 4 |
| Apnex Medical | 12/09 | Series B | $14M | 3 |
| Microchip Biotechnologies | 11/09 | Series B | $18.1M | 5 |
| Zogenix | 10/09 | Series B | $36M | 5 |
| Alimera Sciences | 10/09 | Series C | $5M | 5 |
| Oraya Therapeutics | 7/09 | Series C | $42M | 4 |
| Clovis Oncology | 5/09 | Series A | $145M | 7 |
| Marinus Pharmaceuticals | 5/09 | Series B | $20M | 4 |
| ProteinSimple | 4/09 | Series C | $10M | 7 |
| BiPar Sciences | 1/09 | Series C | $20M | 6 |
| Glaukos | 8/08 | Series D | $35M | 7 |
| Neuron Systems | 8/08 | Series A | $8.96M | 2 |
| GenVault | 6/08 | Series C | $13M | 4 |
| Esperion Therapeutics | 5/08 | Series A | $22.8M | 4 |
| Nuon Therapeutics | 4/08 | Series B | $27M | 2 |
| BioVascular | 2/08 | Series C | $10.9M | 3 |
| Sonexa Therapeutics | 1/08 | Series A | $30M | 5 |
| Zogenix | 1/08 | Venture Round | $18M | 4 |
| Corthera | 12/07 | Series C | $23M | 3 |
| Asmacure Ltée | 5/07 | Series A | $9M | 2 |
| DiObex | 4/07 | Series B | $24M | 6 |
| GenVault | 4/07 | Venture Round | $18M | 2 |
| BiPar Sciences | 2/07 | Series B | $35M | 6 |
| Achaogen | 10/06 | Series B | $26M | 5 |
| CoDa Therapeutics | 10/06 | Series A | $10M | 1 |
| Zogenix | 8/06 | Series A | $60M | 5 |
| ProteinSimple | 1/06 | Series B | $27M | 8 |
| Celladon | 12/05 | Series B | $30M | 4 |
| Alimera Sciences | 11/05 | Series B | $31.8M | 5 |
| DiObex | 9/05 | Venture Round | $7.08M | 3 |
| Five Prime Therapeutics | 2/05 | Venture Round | $45M | 10 |
| Glaukos | 9/02 | Series A | $10M | 3 |
